|1.||Evans, Jilly F: 4 articles (12/2009 - 09/2004)|
|2.||Haeggström, Jesper Z: 3 articles (12/2010 - 05/2006)|
|3.||Bain, Gretchen: 3 articles (12/2009 - 10/2009)|
|4.||Hutchinson, John H: 3 articles (12/2009 - 10/2009)|
|5.||Hakonarson, Hakon: 3 articles (05/2006 - 05/2005)|
|6.||Stefansson, Kari: 3 articles (01/2006 - 05/2005)|
|7.||Helgadottir, Anna: 3 articles (01/2006 - 05/2005)|
|8.||Li, Na: 2 articles (07/2015 - 12/2009)|
|9.||Wang, Qing: 2 articles (07/2014 - 05/2005)|
|10.||Norris, V: 2 articles (02/2014 - 02/2013)|
07/01/2014 - "Previous studies have implicated that two at-risk haplotypes (HapA and HapB) of gene-encoding 5-lipoxygenase-activating protein (ALOX5AP) were significantly associated with stroke. "
01/10/2014 - "Previous studies have indicated that the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene SG13S114 polymorphism is associated with risk of ischemic stroke (IS), but the results remain inconclusive even in Chinese population. "
03/01/2005 - "We recently reported a linkage and association study of MI and stroke that yielded a genetic variant, HapA, in the gene encoding 5-lipoxygenase-activating protein (ALOX5AP), that associates with both diseases in Iceland. "
04/01/2014 - "Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene rs4073259 polymorphism not associated with ischemic stroke in the northeastern Chinese Han population."
01/10/2014 - "The arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene SG13S114 polymorphism and ischemic stroke in Chinese population: a meta-analysis."
08/01/2007 - "This study compares the efficacy of intraplantar administration of indomethacin (a non-selective inhibitor of cyclooxygenase) and MK886 (an inhibitor of 5-lipoxygenase-activating protein), separately or in combination to produce preemptive analgesia in a model of surgical incisional pain in male Wistar rats. "
11/01/2008 - "Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is associated with myocardial infarction in the German population."
02/01/2007 - "In this sample from central Europe, specific polymorphisms in the gene for 5-lipoxygenase-activating protein were not associated with myocardial infarction, a result contrasting previous positive findings."
02/01/2007 - "Haplotypes based on polymorphisms in the gene encoding 5-lipoxygenase-activating protein have been linked with susceptibility to myocardial infarction in Iceland and the United Kingdom. "
02/01/2007 - "No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population."
01/01/2006 - "Variants of the gene ALOX5AP (also known as FLAP) encoding arachidonate 5-lipoxygenase activating protein are known to be associated with risk of myocardial infarction. "
|4.||Asthma (Bronchial Asthma)
02/01/2014 - "This study evaluated the effects of an oral 5-lipoxygenase-activating protein (FLAP) inhibitor, GSK2190915, in patients with asthma and elevated sputum neutrophils. "
03/01/2014 - "This double-blind, placebo-controlled, five-way crossover study investigated the dose response and duration of action of a 5-lipoxygenase-activating protein inhibitor, GSK2190915, to inhibit EIB in subjects with asthma. "
12/01/2013 - "Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma."
02/01/2013 - "The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma."
01/01/2013 - "GSK2190915 is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the treatment of asthma. "
|5.||Cardiovascular Diseases (Cardiovascular Disease)
03/01/2006 - "Arachidonate 5-lipoxygenase activating protein (ALOX5AP) gene is involved in the pathogenesis of atherosclerotic cardiovascular disease (CVD). "
07/01/2006 - "Human genetic studies as well as disruption of the 5-LO gene in mouse models of hyperlipidemia revealed that 5-LO and 5-LO-activating protein are associated with risks of human cardiovascular disease, and that this cascade plays an important role in aortic aneurysm pathogenesis through leukotriene-mediated inflammatory chemokine production. "
09/01/2004 - "Genetic studies have associated 5-LO and its accessory protein, 5-LO-activating protein, with cardiovascular disease, myocardial infarction and stroke. "
04/17/2009 - "MK-886, an inhibitor of the 5-lipoxygenase-activating protein (FLAP), potently suppresses leukotriene biosynthesis in intact cells and is frequently used to define a role of the 5-lipoxygenase (EC 184.108.40.206) pathway in cellular or animal models of inflammation, allergy, cancer, and cardiovascular disease. "
|2.||Type 4 Cyclic Nucleotide Phosphodiesterases
|4.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|5.||Arachidonate 5-Lipoxygenase (5 Lipoxygenase)
|7.||Messenger RNA (mRNA)
|8.||Proteins (Proteins, Gene)
|9.||Biological Markers (Surrogate Marker)
|10.||Insulin Receptor Substrate Proteins